Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why ...

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients ...